(±)-lucidumone是从灵芝属赤芝Ganoderma lucidum中分离得到的一种含量低微的新型杂萜类天然产物，具有包含6个连续手性中心的6/5/6/6/5多环骨架。初步生物活性表明(–)-lucidumone对环氧化酶COX-2具有明显的选择性抑制作用（IC50=5.62 μM），为新型抗炎药物研发奠定基础。本项目拟分别采取以分子间不对称Diels-Alder反应和手性胺催化的不对称[4+2]型环加成反应为关键步骤的两条合成策略，探索和发展新颖高效和普适性的合成方法，完成lucidumone的首次不对称全合成研究。本项目对有机合成方法学，尤其是同类天然产物合成及生理活性研究具有重要的学术价值。

(±)-lucidumone, an enantiomeric meroterpenoid possessing an unprecedented skeleton comprising a fused 6/5/6/6/5 polycyclic system, was isolated from Ganoderma lucidum and yield 4.5×10‒6 %. Preliminary bioassay results showed (–)-lucidumone could inhibit the enzyme activity of COX-2 significantly (IC50 = 5.62 μM), which will be the foundation for next generation COX-2 inhibitor development. In our proposed study, we plan to respectively use the intermolecular asymmetric Diels–Alder reaction and an organocatalytic formal [4+2] cycloaddition reaction as the key procedures,, and develop more efficient and flexible methods for the enantioselective total synthesis of lucidumone. This project will prove its important academic value in the field of synthetic organic chemistry, especially for the total synthesis and the bioactivity investigation of complex natural products and their analogues.